<DOC>
	<DOCNO>NCT00575978</DOCNO>
	<brief_summary>This study conduct phase I/II clinical trial . In addition determine maximum tolerate dose ( MTD ) hydralazine , phase I trial perform identify unexpected toxicity may occur hydralazine use conjunction neoadjuvant chemotherapy normotensive woman breast cancer . Once phase I trial successfully complete , phase II trial evaluate efficacy hydralazine produce demethylation effect begin .</brief_summary>
	<brief_title>Hydralazine Demethylating Agent Breast Cancer</brief_title>
	<detailed_description>The objective study determine MTD hydrazaline add standard neoadjuvant chemotherapy operable breast cancer . Four dose level hydrazalline plan : Dose Level 1 : 150 mg/d 50 mg PO TID Dose Level 2 : 200 mg/d 50 mg PO QID Dose Level 3 : 225 mg/d 75 mg PO TID Patients treat cohort 3 patient may treat one dose level . Additional cohort may initiate toxicity fully evaluate current cohort patient . The MTD exceed dose level produce dose limit toxicity ( DLT ) least two three patient cohort . Dose escalation proceed increase dose accord follow table . Number Events/Number Cohort Action 0/3 Proceed next dose level 1/3 Accrue 3 patient dose 1/3 + 0/3 Proceed next dose level 1/3 + 1/3 Stop : Previous dose level MTD 1/3 + 2/3 Stop : Previous dose level MTD 1/3 + 3/3 Stop : Previous dose level MTD 2/3 Stop : Previous dose level MTD 3/3 Stop : Previous dose level MTD If MTD exceed dose escalation one cohort observe toxicity test previous dose level , additional cohort 3 patient test previous dose level . Thus , six patient must treat dose declare MTD . In unlikely event 150 mg/day hydralazine , start dose , produce two DLTs , daily dose hydralazine reduce 50mg to100 mg/day . If two toxicity observe reduce dose level , study stop phase II study perform . This phase I study require 9 24 patient . The cohort six patient treat MTD use subsequent phase II trial . Definition Dose Limiting Toxicities Because study drug cytotoxic agent , `` add '' toxic chemotherapy regimen woman likely normotensive , drug evaluate cardiovascular literature maximum clinical dos 300 mg/d , make follow decision deviate classic `` cytotoxic '' agent scheme . The deviation follow : - Dose escalation beyond `` CLINNICALLY MAXIMAL '' dose 250 mg/d plan , - The definition DLT adhere NCI CTC - design cytotoxic agent , rather simply tolerability drug patient document protocol reproduce : 1 . Symptomatic hypotension , 2 . Blood pressure record &lt; 90 mmHg systolic , &lt; 55 mgHg diastolic , 3 . Other side effect deem unacceptable either patient treating physician , 4 . Patient request/refusal continue study . Patients go drug consider DLT event .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hydralazine</mesh_term>
	<criteria>Patients refer breast cancer service diagnostic evaluation `` breast growth '' candidate participate study . Patients history elevate blood pressure already antihypertensives would ideal candidate project . In situation , hydralazine replace antihypertensive . There age limit study . Inclusion criterion follow : 1 . Operable `` invasive '' breast cancer 2 . Signed informed consent 3 . Baseline blood pressure OFF antihypertensives &gt; 110/60 mmHg 1 . Preexisting hypotension 2 . Preexisting liver disease ( liver function test &gt; 2x upper limit normal ULM ) . 3 . Preexisting kidney ( serum creatinine &gt; 2 mg/dl ) . 4 . Medical necessity remain betablockers meet agent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>breast cancer</keyword>
</DOC>